Mobile website
Archive > Volume 20 Issue 4 > 2013,20(4):383-390. DOI:10.3872/j.issn.1007-385X.2013.04.001 Prev Next
Editorial
New strategy of tumor immunotherapy based on chimeric antigen receptor engineered T cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Chimeric antigen receptor (CAR)-engineered T cell is a newly developed strategy of adoptive immunotherapy. Its unique theoretical superiority and attractive application prospects open up a promising arena for anticancer therapy. CAR combines single chain variable fragment (scFv) antibody recognizing tumor-associated antigen with T cell activation motif, which endows T cells with tumor-orientated targeting ability, stronger killing activity, and prolonged survival by genetic modification. Since first proposed by Dr. Eshhar in 1989, CAR has been developed from the first generation to the second and the third generations containing costimulatory molecular. The clinical trials in leukemia, lymphoma, and melanoma have obtained exciting results. However, the off-target effect, cytokine strom, and graft-versus-host disease are potential challenges for clinical use. Future research will focus on designing safer CAR of the fourth generation, selecting good therapeutic T cell subsets, optimizing clinical scheme of administration, and improving pre-clinical models. It is believed that the obstacles from bench to clinic will be cleared and that CAR will become one of the main cancer therapies with breakthroughs in immunology, gene therapy and cell engineering.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China （No. 81172415，No.81241077），and the Key cientificand Technological Project of Henan Province （No. 102102310065）
Clc Number:
